Immunotherapy in advanced, G12C-mutant non-small-cell lung cancer: current strategies and future directions
Kirsten rat sarcoma ( KRAS ) mutations are present in up to 25% of non-small-cell lung cancer (NSCLC). KRAS G12C is the most common type of mutation, representing approximately half of the cases in KRAS -mutant NSCLC. Mutations in KRAS activate the RAF-MEK-ERK pathway, leading to increased cell prol...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251323985 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|